At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 244 enrolled
Drug / intervention
Injectafer +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
IRON CLAD: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose Injection) in Adults
In Brief
A Phase 3 clinical trial evaluating Injectafer and Normal Saline for Cancer and Chemotherapy Related Anemia. Completed, enrolled 244 participants across 29 sites.
Detailed Summary
Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer and Chemotherapy Related Anemia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
First PostedMay 2015
Primary CompletionJan 2018
Study CompletionJan 2018
TodayJul 2026
First PostedMay 25, 2015
Enrollment StartMay 23, 2015
Primary CompletionJan 1, 2018
Study CompletionJan 4, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.1 years ago
Interventions
Injectaferdrug
Normal Salineother